Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Genetic Immunity Publishes the Technology Roadmap for the Cure of HIV

Abstract:
Genetic Immunity (OTCBB: PWRV), a leader in immunotherapy technology, announced the peer-reviewed publication on the Company's groundbreaking nanotechnology and details on its potential for the cure of HIV. The manuscript is entitled "Nanomedicine applications Towards the Cure of HIV" by J. Lisziewicz and E. R. Toke (www.nanomedjournal.com/article/S1549-9634(12)00287-0/abstract).

Genetic Immunity Publishes the Technology Roadmap for the Cure of HIV

Budapest, Hungary | Posted on October 22nd, 2012

The Scientists of Genetic Immunity pioneered research for the cure of HIV: in 1999 they described in the New England Journal of Medicine the first patients whose immune system was boosted to control HIV after interruption of his daily drug treatment (www.nejm.org/doi/full/10.1056/NEJM199905273402114). This observation inspired development of a new medicine called DermaVir that boosts the immune system to specifically recognize and kill HIV infected cells. Today, DermaVir is the most advanced nanomedicine developed for the cure of HIV.

"We have about 30 potent HIV drugs suppressing viral load, but we do not have any to eliminate the infected cells from the reservoirs. To cure HIV we need new drugs to activate these infected cells and to kill them. In our manuscript we described the new drugs that are needed and the strategy that will result in the cure of HIV. One of these new essential drugs for HIV eradication is DermaVir, our lead HIV-specific immunotherapeutic product. In contrast to the daily oral drugs, DermaVir is administered a few times a year with four patches. Our Clinical Trials have shows DermaVir to be as safe as a placebo and it induced long-lasting HIV-specific T cell production. Our GIEU006 Phase II trial demonstrated significant killing of HIV-infected cells, producing 70% viral load reduction compared to a placebo. Our results suggest that DermaVir provides the immunologic drug component towards the eradication of HIV," said Dr. Julianna Lisziewicz, CEO of Genetic Immunity.

Eradication of HIV is a difficult goal to achieve, because a reservoir of HIV is established soon after infection and it persists even after years of potent antiretroviral treatment. New drugs under development can activate dormant HIV and flush the virus from the reservoirs. However, activation is not enough, HIV-infected cells must be detected and killed by the immune system. In Hepatitis C, which is caused by a virus transmitted through the blood similarly to HIV, the cure rate is up to 75% because the use of drugs that suppress virus replication and induce the immune system to fight the virus. Up to now the cure of HIV has not been achieved with drugs that suppress the virus. Therefore, DermaVir will be required to induce the immune system to fight HIV and contribute to the cure of HIV/AIDS.

Genetic Immunity is a wholly owned subsidiary of Power of the Dream Ventures, Inc. (OTCBB: PWRV).

####

About Power of the Dream Ventures, Inc
Genetic Immunity, a wholly owned subsidiary of Power of the Dream Ventures, Inc. (OTCBB: PWRV), is a clinical stage technology company committed to discovering, developing, manufacturing and commercializing a new class of immunotherapeutic biologic drugs for the treatment of viral infections, cancer and allergy. Our Langerhans cell targeting nanomedicines are exceptional in both safety and immune modulating activity boosting specific Th1-type central memory T cells. These are essential to eliminate infected cells or cancerous cells, and balance the immune reactivity in response to allergens.

In 1988 Drs. Lisziewicz and Lori founded Genetic Immunity in the US after they described the 1st patient whose immune system was boosted to control HIV after treatment interruption (Lisziewicz et al. New England Journal of Medicine 1999) that lead to the invention of DermaVir. The Company's innovative technology team directed by Dr. Lisziewicz, a champion of immune boosting therapies, is now headquartered in Budapest, Hungary. She has been invited into the Scientific Advisory Board of the HIV Cure Initiative led by Francoise Barre-Sinoussi, Nobel Prize Laureate for her HIV research in 2009. For more information please visit www.geneticimmunity.com

For more information, please click here

Contacts:
Dr. Zsolt Lisziewicz
Chief Operating Officer
Genetic Immunity, Inc.
Phone: +36-1-272-0364
Cell: +26-30-211-6402

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Related News Press

News and information

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Possible Futures

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Researchers peer into atom-sized tunnels in hunt for better battery: May improve lithium ion for larger devices, like cars December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Discoveries

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Researchers peer into atom-sized tunnels in hunt for better battery: May improve lithium ion for larger devices, like cars December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Announcements

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Researchers peer into atom-sized tunnels in hunt for better battery: May improve lithium ion for larger devices, like cars December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Researchers peer into atom-sized tunnels in hunt for better battery: May improve lithium ion for larger devices, like cars December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project